Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics
Status:
Completed
Trial end date:
2018-02-06
Target enrollment:
Participant gender:
Summary
Both macitentan and riociguat are indicated in the treatment of pulmonary arterial
hypertension (PAH) and may be administered concomitantly. The primary objective of this study
is to evaluate the effect of macitentan administered for 11 days on the pharmacokinetics (PK)
(i.e., amount and time of presence in the blood of riociguat) of a single dose of riociguat
in healthy male subjects.